Skip to content

The trial will be conducted in five African countries, three in west Africa (Burkina-Faso, Mali and The Gambia), where malaria transmission is highly seasonal, and higher in Burkina Faso and Mali than in The Gambia, one Southern Africa (Mozambique), where malaria is moderate and HIV is highly prevalent, and one Central Africa (Democratic Republic of the Congo, DRC), where malaria transmission is intense and across the whole year. The Mozambican and Congolese sites will carry out the study component on Pyronaridine-Artesunate’s (PA) interactions with antiretroviral treatment.